Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Sees Large Decrease in Short Interest

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) was the recipient of a significant decline in short interest in February. As of February 13th, there was short interest totaling 1,875 shares, a decline of 96.4% from the January 29th total of 52,373 shares. Approximately 0.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 23,155 shares, the short-interest ratio is presently 0.1 days. Based on an average daily trading volume, of 23,155 shares, the short-interest ratio is presently 0.1 days. Approximately 0.1% of the shares of the stock are short sold.

Institutional Trading of Scinai Immunotherapeutics

A hedge fund recently raised its stake in Scinai Immunotherapeutics stock. Citadel Advisors LLC raised its holdings in shares of Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) by 146.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 28,630 shares of the company’s stock after purchasing an additional 17,031 shares during the period. Citadel Advisors LLC owned 0.90% of Scinai Immunotherapeutics worth $36,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 58.41% of the company’s stock.

Scinai Immunotherapeutics Stock Up 5.9%

NASDAQ:SCNI traded up $0.05 during trading hours on Wednesday, hitting $0.91. 64,261 shares of the stock were exchanged, compared to its average volume of 26,672. The company has a market capitalization of $3.16 million, a P/E ratio of -0.10 and a beta of 1.88. The company’s 50 day moving average is $0.83 and its two-hundred day moving average is $1.15. Scinai Immunotherapeutics has a twelve month low of $0.61 and a twelve month high of $6.18.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Scinai Immunotherapeutics in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Scinai Immunotherapeutics currently has an average rating of “Sell”.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.

Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts.